Medpage Today on MSN1d
Real-World Data on the RSV Vaccine for Older AdultsRegarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...
Medpage Today on MSN1d
Which High-Risk Patients Should Get the RSV Vaccine?The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...
Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...
GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...
Hosted on MSN5d
Year in Review: RSVIn June, the FDA expanded the approval of GSK's RSV vaccine (Arexvy) to include adults ages 50-59 at increased risk of lower ...
Investor's Business Daily on MSN5d
Moderna Posts A Surprise Profit As Sales Wallop Views. But Will RSV Be Its Undoing?Moderna crushed third-quarter expectations on Thursday and turned around a surprise profit, sending Moderna stock higher in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback